Blockchain in the pharmaceutical industry is mainly used to share a tamper-evident record of serialized medicine packages between manufacturers, wholesalers and pharmacies, in support of laws such as the US Drug Supply Chain Security Act (DSCSA).
This guide explains what DSCSA and the EU Falsified Medicines Directive require, where a ledger helps, where it does not, and how to design a network. Regulators require traceability results, not a specific technology, and many compliant systems run without any blockchain.
Drug traceability rules
United States: DSCSA
Congress passed the DSCSA in 2013. It requires an electronic, interoperable system that traces each prescription drug package through the supply chain. Each package carries a product identifier in a 2D barcode that holds the National Drug Code (NDC), a serial number, the lot number and the expiration date. Trading partners must:
- Exchange transaction information electronically for each sale.
- Verify the product identifier of a suspect product.
- Respond quickly to investigations and recalls.
The enhanced requirements started in November 2023, and the FDA then set a one-year stabilization period and gave staggered exemptions by trading partner type. Exemptions for manufacturers, repackagers, wholesale distributors and large dispensers ran out during 2025. Small dispensers with 25 or fewer full-time employees received the longest exemption, and the FDA issued a new notice for them in August 2026. The FDA's DSCSA pages list the current dates.
European Union: Falsified Medicines Directive
The EU uses a different model: since February 2019, most prescription medicines carry a unique identifier and an anti-tampering device. A pharmacy scans each pack and removes its identifier from the system when the pack is dispensed, and the check runs against a central repository network that industry groups operate. The EU model checks a pack at both ends of the chain and does not trace every step, which shows that a central architecture can meet regulatory goals.
Uses of blockchain in pharma
| Use case | What a shared ledger adds | What stays off the chain |
|---|---|---|
| DSCSA transaction tracing | A common, tamper-evident record of ownership changes that no single trading partner controls | Commercial details, prices and customer identities |
| Saleable returns verification | A wholesaler can confirm that a returned serial number is genuine before resale | The manufacturer's master serial database |
| Trading partner credentials | Verifiable proof that a counterparty is an authorized trading partner under DSCSA | The license documents themselves |
| Cold chain integrity | Hashes of sensor readings that prove the temperature history of vaccines and biologics | Raw sensor data streams |
| Clinical trial data integrity | Hashes of protocols, consent form versions and datasets that prove no one changed them later | All patient data and trial records |
The FDA ran a DSCSA pilot program in 2019 and 2020, and several pilots tested blockchain networks. The final reports focused less on the ledger and more on data standards, identifiers and agreement between trading partners. Industry groups later built DSCSA networks on blockchain, such as MediLedger for saleable returns, and the Open Credentialing Initiative uses W3C verifiable credentials to prove that a partner is authorized.
DSCSA blockchain design: where a ledger does not belong
- Patient data. Never put protected health information on a ledger, even in encrypted form. HIPAA, GDPR and patients' rights over their data conflict with permanent copies on many nodes. The guide to EHR software development explains how health data should be handled.
- The manufacturer's serialization system. Serial number generation and packaging-line integration stay in conventional systems.
- Problems inside one company. Internal batch genealogy belongs in a validated manufacturing execution system (MES).
- Proof that a pill is genuine. A ledger tracks identifiers, not the product, so a counterfeiter who copies a valid barcode can pass any system that does not check for duplicate scans.
How to design a pharma traceability network
- Start from the regulation. Map each DSCSA or FMD duty to a system function and a data element.
- Adopt the standards your partners already use, mainly GS1 identifiers and GS1 EPCIS events for serialized data.
- Decide governance. Agree who runs nodes, how manufacturers, distributors and pharmacies join, and who pays.
- Keep on-chain data small. Store hashes, identifiers and attestations on the ledger, and share commercial data directly between partners under access control.
- Validate the system under GxP rules for computerized systems, with documented tests and change control.
- Integrate with ERP, warehouse and pharmacy systems, and with existing verification services.
- Pilot with real partners and measure investigation response times and exception rates before you scale.
Most pharma networks use a permissioned ledger, because members are known and commercial data is sensitive. The guide to private blockchain development explains the trade-offs. The guide to blockchain supply chain systems covers the general traceability architecture, and the guide to blockchain IoT covers cold-chain sensors.
Cost and adoption
Pharma IT changes slowly because of validation, audits and patient safety. Projects face long procurement cycles, large amounts of documentation and integration work with each trading partner. A blockchain network is worth its cost only when many partners use it, and a network of one manufacturer and one distributor offers little over a direct integration between the two. The article on blockchain in healthcare covers the wider health sector.
Frequently asked questions
Does DSCSA require blockchain?
No. DSCSA requires electronic, interoperable tracing, verification and data exchange. Blockchain is one possible architecture, and many solutions use conventional networks and standard EPCIS messages.
Can blockchain stop counterfeit drugs?
A ledger makes changes to traceability records detectable and can flag duplicated serial numbers, but it still depends on accurate scans and checks at each step. Packaging security and enforcement remain necessary.
Is a public blockchain suitable for pharma traceability?
Commercial supply data is sensitive, so most projects use a permissioned network, or keep data off the chain and write only hashes to a public chain.
How is blockchain used in pharma besides DSCSA?
Common uses are cold chain records for vaccines and biologics, and hashes that prove clinical trial documents did not change.